<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439917</url>
  </required_header>
  <id_info>
    <org_study_id>17086</org_study_id>
    <secondary_id>17/EM/0441</secondary_id>
    <nct_id>NCT03439917</nct_id>
  </id_info>
  <brief_title>Effects of Carnitine Supplementation on Liver and Muscle</brief_title>
  <acronym>ECLIPSE</acronym>
  <official_title>Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves
      metabolism in individuals who have a high concentration of fat within their liver.
      Participants will be given either Carnitine or placebo, together with a meal replacement
      milkshake twice daily for 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NAFLD occurs when too much fat accumulates in liver tissue. This can, over time, cause
      inflammation and scarring of the liver, eventually leading to chronic liver disease and
      cirrhosis. It is strongly associated with diabetes and obesity, both of which are endemic in
      Western societies.

      Carnitine enables cells in the body to use fat as a fuel, and recent studies have suggested
      that carnitine supplementation may reduce liver triglyceride content. Muscle and liver are
      the major sites in the body which coordinate glucose and fat metabolism. As well as assessing
      the effect of carnitine supplementation on liver fat, its effect on metabolic processes
      within these tissues will also be measured
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrahepatic triglyceride (IHTG) content</measure>
    <time_frame>24 weeks</time_frame>
    <description>IHTG measured by proton magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver sensitivity to insulin</measure>
    <time_frame>24 weeks</time_frame>
    <description>suppression of glucose output from the liver during a 20 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole body insulin sensitivity</measure>
    <time_frame>24 weeks</time_frame>
    <description>whole body glucose uptake during a 50 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle lipid content</measure>
    <time_frame>24 weeks</time_frame>
    <description>lipid content of the vastus lateralis muscle measured by proton magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle sensitivity to insulin</measure>
    <time_frame>24 weeks</time_frame>
    <description>Arterialised-venous vs. femoral venous difference in blood glucose concentration during the last hour of a 2 hour 50 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole body composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fat and lean tissue mass assessment by dual energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver energy metabolism</measure>
    <time_frame>24 weeks</time_frame>
    <description>hepatic ATP flux assessed by 31-phosphorous magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Carnitine and Meal Replacement Drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Meal Replacement Drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Carnitine tartrate</intervention_name>
    <description>2g L-Carnitine tartrate as a powder consumed twice a day</description>
    <arm_group_label>Carnitine and Meal Replacement Drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Meal Replacement Drink</intervention_name>
    <description>325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day</description>
    <arm_group_label>Carnitine and Meal Replacement Drink</arm_group_label>
    <arm_group_label>Placebo and Meal Replacement Drink</arm_group_label>
    <other_name>Slimfast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day</description>
    <arm_group_label>Placebo and Meal Replacement Drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elevated liver fat on screening abdominal ultrasound

          -  Capable of providing informed consent

          -  Non-vegetarian diet

          -  BMI &lt;40 kg/m2

          -  Weekly ethanol consumption &lt;21 units/week

          -  Negative non-invasive liver screen, including Hepatitis B and C serology, liver
             autoantibodies, transferrin saturation, Î±1-antitrypsin levels.

        Exclusion Criteria:

          -  Known history of cardiovascular disease

          -  Known diabetes mellitus

          -  Known psychiatric comorbidity

          -  Chronic kidney disease

          -  Surgery within 6 months prior to start of study

          -  Exposure to drugs known to influence hepatic steatosis (including steroids, statins,
             omega-3-fatty acids)

          -  Current smokers

          -  Contraindications to magnetic resonance scanning, including implanted ferrous material
             (implantable pacemakers or defibrillators), metallic ocular foreign bodies,
             ferromagnetic aneurysm clips or severe claustrophobia.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guru Aithal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prarthana Thiagarajan, MD</last_name>
    <phone>+44 (0) 115 9709966</phone>
    <email>Prarthana.Thiagarajan@nottingham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liz J Simpson, PhD</last_name>
    <phone>+44 (0) 1158230128</phone>
    <email>liz.simpson@nottingham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David Greenfield Human Physiology Unit</name>
      <address>
        <city>Nottingham</city>
        <state>Notts</state>
        <zip>NG72UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Brown</last_name>
      <phone>+44(0)115 8230434</phone>
      <email>sara.brown@nottingham.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Liz Simpson, PhD</last_name>
      <phone>+44(0)1158230128</phone>
      <email>liz.simpson@nottingham.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Paul L Greenhaff, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian A macdonald, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

